Global
Clinical Trials announces the first successful screening in the endometriosis
study.
It
is a Phase III double-blind, three-arm superiority study in 200+ subjects that is
being conducted in Ukraine. The study aims to assess the safety and efficacy of
the Investigational Product (IP) for treatment of endometriosis in women of
reproductive age.
GCT
has been running Women’s Health clinical trials since 2001, and it is one of
GCT’s main–focus therapeutic areas. GCT is well–familiar with Key Opinion
Leaders (KOLs) and clinical sites, and utilizes this expertise to ensure an
effective enrollment of patients for its projects.
“GCT is proud to achieve this
milestone in such a short time. Together, GCT, sites, and the Sponsor’s team
engaged all their efforts to make it happen, “ said Dr. Eugene Selivra, GCT
CEO.
Endometriosis
is an incurable but manageable gynecological condition. It occurs when
endometrial implants, comprised of tissue normally found within the uterus, are
present in other areas of the body. It is a long-term condition that can have a
significant impact on the life of the patient.
To plan a new endometriosis
clinical trial with GCT, please contact us at bd@gctrials.com.